What targeted therapies are available for Colorectal Cancer

Targeted Therapies for Colorectal Cancer

Targeted therapies are medications designed to attack specific genetic mutations or proteins found in cancer cells. For colorectal cancer, the choice of targeted therapy depends heavily on your tumor's biomarker profile—essentially, the genetic "fingerprint" of your cancer. Let me walk you through the main options.

How Doctors Decide Which Targeted Therapy to Use

According to NCCN Guidelines for Colon Cancer, your oncologist will test your tumor for specific mutations to determine which targeted therapies might work best. The key biomarkers they look for include:

• KRAS/NRAS/BRAF mutations (genes that control cell growth)
• HER2 amplification (a protein that promotes cancer cell growth)
• Mismatch repair (MMR) status or microsatellite instability (MSI-H) (related to how well cells repair DNA)
• POLE/POLD1 mutations (ultra-high mutation burden)

---

Main Targeted Therapy Options

1. EGFR Inhibitors (for KRAS/NRAS/BRAF Wild-Type Tumors)

What they target: EGFR (epidermal growth factor receptor), a protein that tells cancer cells to grow

Medications include:

• Cetuximab
• Panitumumab

When they're used: These work best in patients with left-sided colon cancers that do NOT have KRAS, NRAS, or BRAF mutations. According to NCCN Guidelines, these are often combined with chemotherapy regimens like FOLFOX or FOLFIRI.

Important note: If you can't tolerate EGFR inhibitors due to side effects, your doctor may consider single-agent alternatives like adagrasib or sotorasib.

---

2. BRAF Inhibitors (for BRAF V600E Mutations)

What they target: BRAF, a mutated gene that drives cancer growth in about 5-10% of colorectal cancers

Medication:

• Encorafenib (often combined with cetuximab or panitumumab PLUS chemotherapy like FOLFOX)

Why it matters: BRAF-mutated colorectal cancers tend to be more aggressive, so combination therapy is typically recommended according to NCCN Guidelines.

---

3. HER2-Targeted Therapies (for HER2-Amplified Tumors)

What they target: HER2, a growth-promoting protein found in about 2-5% of colorectal cancers

Medications include:

• Trastuzumab (Herceptin) - a monoclonal antibody
• Pertuzumab (Perjeta)
• Lapatinib - a tyrosine kinase inhibitor
• Tucatinib - a newer HER2 inhibitor
• Trastuzumab deruxtecan (T-DXd) - an antibody-drug conjugate (a targeted therapy attached to chemotherapy)

When used: For patients with HER2-amplified, RAS and BRAF wild-type tumors, according to NCCN Guidelines.

---

4. KRAS Inhibitors (for KRAS G12C Mutations)

What they target: KRAS G12C, a specific mutation in the KRAS gene found in about 3-4% of colorectal cancers

Medications include:

• Sotorasib (Lumakras)
• Adagrasib (Krazystas)

Important consideration: These are often combined with EGFR inhibitors (cetuximab or panitumumab) for better effectiveness. However, NCCN Guidelines note that if you're unable to tolerate EGFR inhibitors due to toxicity, single-agent KRAS inhibitors can be considered.

---

5. Immunotherapy for MMR-Deficient/MSI-H Tumors

While not traditional "targeted" therapy in the genetic sense, checkpoint inhibitor immunotherapy targets the immune system's ability to fight cancer in patients with specific DNA repair deficiencies.

Medications include:

• Nivolumab (Opdivo)
• Pembrolizumab (Keytruda)
• Dostarlimab (Jemperli)
• Cemiplimab (Libtayo)

When used: For patients with dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high) tumors, according to NCCN Guidelines. These have shown durable responses in advanced colorectal cancer.

---

How These Are Combined with Chemotherapy

According to NCCN Guidelines, targeted therapies are typically not used alone in advanced colorectal cancer. Instead, they're combined with standard chemotherapy regimens:

• FOLFOX (fluorouracil + leucovorin + oxaliplatin)
• FOLFIRI (fluorouracil + leucovorin + irinotecan)
• CAPEOX (capecitabine + oxaliplatin)

For example, if you have a KRAS wild-type, left-sided tumor, your doctor might recommend FOLFOX + cetuximab rather than FOLFOX alone.

---

Important Questions to Ask Your Oncologist

1. What is my tumor's biomarker profile? (KRAS, NRAS, BRAF, HER2, MMR/MSI status)
2. Which targeted therapy do you recommend for my specific mutations, and why?
3. Will this be combined with chemotherapy, and if so, which regimen?
4. What are the expected side effects, and how will we manage them?
5. Are there clinical trials available for my biomarker profile?
6. How will we monitor whether the targeted therapy is working?
7. What happens if my cancer becomes resistant to this targeted therapy?

---

Key Takeaway

Targeted therapies for colorectal cancer are increasingly personalized based on your tumor's specific genetic mutations. The NCCN Guidelines emphasize that biomarker testing at diagnosis is essential because treatment recommendations vary considerably based on these results. Your oncologist will use your tumor's genetic profile to select the most appropriate targeted therapy—or combination of therapies—for your individual case.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.